Huan Qiu Wang·2025-06-16 10:52Core Viewpoint - Fosun Pharma has successfully completed the first batch shipment of its self-developed drug, Luwo Meitini Tablets (Fumainin®), marking its imminent clinical use and addressing patient medication needs [1][5]. Group 1: Product Launch and Approval - Fumainin® is the first and only targeted drug in China approved for dual indications: adult Langerhans cell histiocytosis (LCH) and tissue tumors, as well as type I neurofibromatosis for children aged 2 and above [1][6]. - The drug received approval from the National Medical Products Administration through a priority review and approval process by the end of May 2025 [5]. Group 2: Logistics and Distribution - The first batch of Fumainin® was successfully shipped from the production base of the entrusted manufacturer, Kelaiying Pharmaceutical Group, located in Tianjin [3]. - The logistics team completed a series of complex tasks within 10 working days after obtaining the approval, demonstrating efficient execution and a strong commitment to patient needs [5]. Group 3: Industry Impact and Responsibility - The rapid approval of Fumainin® fills a treatment gap in the rare disease oncology field in China, representing a significant breakthrough in domestic original innovation [6]. - The company emphasizes its responsibility to ensure that Fumainin® reaches patients in need as quickly as possible, reflecting a strong sense of social responsibility [6].